Lathosterol and Noncholesterol Sterols in Routine Use for the Differentiation and Monitoring of Dietary and Drug Induced Treatment of Hypercholesterolemias in Children and Adolescents
DOI:
https://doi.org/10.6000/1929-5634.2014.03.01.1Keywords:
Noncholesterol sterols, lathosterol, desmosterol, campesterol, sitosterol, phytosterols, heterozygous familial hypercholesterolemia, statins, ezetimibe, dietary and drug treatmentAbstract
Aims: The authors discuss their 15 years of experience with use of noncholesterol sterols (NCS) when diagnosing heterozygous familial hypercholesterolemia (HFH) and the dietary and drug treatment of children and adolescents when lathosterol (Lat) and desmosterol (Des) as cholesterol synthesis precursors, and campesterol (Cam) and sitosterol (Sit) as cholesterol absorption precursors are included.
Patients and Methods: 38 children and adolescents (6-18 yrs) with HFH proven by molecular genetic testing of LDL-cholesterol receptor deficit; 107 children patients with clinical and laboratory symptoms of other hypercholesterolemias; 84 healthy school-age children as a control group. Routine lipid spectrum scan—total cholesterol (TCh), LDL-Ch, HDL-Ch, TAG, with additional apo A1, apo B, Lp (a), LDL-receptors, apo E polymorphism; Lat, Des, Cam and Sit in the plasma—was established by means of GC/MS.
Results: The HFH patients on a low cholesterol diet (LCHD) who come to our lipid outpatient clinic have elevated levels of Lat and Des, unlike patients with alimentary hypercholesterolemia (p<0, 001). Lat and Des levels are high following interruption of medical treatment during long vacations or when drug treatment is neglected. Administration of statins only in sufficiently high therapeutic doses reduces Lat and Des (p<0, 001). Compensatory elevation of Cam and Sit occurs only in few pediatric patients. Ezetimibe decreases Cam and Sit more efficiently than Lat or Des. Combination of statin with ezetimibe is most efficient in decrease of not only TCh but also Lat and Des, as well as Cam and Sit.
Conclusions: Extending the laboratory spectrum by precursors of cholesterol synthesis and absorption improves the differential diagnosis of HFH and makes monitoring and/or treatment of children and adolescents more precise.
References
Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Pediatrics 2011; S 213-S256.
Magnussen CG, Venn A, Thomson R, et al. The association of pediatric low-density lipoprotein cholesterol and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia satus with carotid intimal-media thickness in adulthood evidence from the cardiovascular risk in Young Finns Study, the Bogalusa Heart Study, and the CDAH (Childhood Determinants of Adult Health) Study. J Am Coll Cardiol 2009; 53: 860-69. http://dx.doi.org/10.1016/j.jacc.2008.09.061
McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a specific statement from the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115: 1948-67. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.181946
Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005; 112: 2061-75. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169251
deJongh S, Ose L, Szamosi T, Gagne C, Lambert M, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo controlled trial with simvastatin. Circulation 2002; 106: 2231-37. http://dx.doi.org/10.1161/01.CIR.0000035247.42888.82
Wiegman A, Hutten BA, deGroot E, et al. Efficacy and safety of statin therapy in children with familial hypercholestero-lemia: a randomized controlled trial. JAMA 2004; 292: 331-37. http://dx.doi.org/10.1001/jama.292.3.331
Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia. The younger, the better. Circulation 2007; 116: 664-68. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.671016
Avis HJ, Hutten BA, Gagné V, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55: 1121-26. http://dx.doi.org/10.1016/j.jacc.2009.10.042
Gauer R. Hyperlipidemia treatment in children: The younger, the better. Am Family Physician 2010; 82: 462-77.
Clauss S, Wai KM, Kavey RW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediat 2009; 154: 869-72. http://dx.doi.org/10.1016/j.jpeds.2008.12.044
Health Regulations—Preventive Screenings. Bulletin of the Czech Ministry of Health, 7/1994 (in Czech).
Miettinen TA. Cholesterol precursors and thein diurnal rhytm in lipoproteins of patients with jejunoileal bypass and ileal dysfunction. Metabolism 1985; 34: 425-30. http://dx.doi.org/10.1016/0026-0495(85)90207-0
Kempen HJM, Glaatz JFC, Leuven JAG, et al. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res 1988; 29: 1149-55.
Miettinen TA, Tilovbis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volonteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20-31.
Jones PJ, Schoelleer DA. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res 1990; 312: 667-73.
Hamilton JJ, Hany M, Innis SM. Elevation of plasma lathosterol, as indicator of increased cholesterol synthesis in preterm infants given Intralipid. Pediat Res 1992; 31: 186-92. http://dx.doi.org/10.1203/00006450-199202000-00020
Miettinen TA, Gylling H, Strandberg TE, et al. for Finish 4S Investigators. Baseline serum cholestanol as predictor of recurrent coronary events in subgroups of Scandinavian Simvastatin Survival Study. Br Med J 1998; 316: 1127-30. http://dx.doi.org/10.1136/bmj.316.7138.1127
Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest 2003; 33: 967-82. http://dx.doi.org/10.1046/j.1365-2362.2003.01229.x
Gylling H. Cholesterol metabolism and its implications for therapautic interventions in patients with hypercholesterolemia. Int J Clin Practice 2004; 58: 859-66. http://dx.doi.org/10.1111/j.1742-1241.2004.00351.x
Gylling H, Miettinen TA. The effect of plant stanol- and sterol-enriched foods on lipid metabolism, serum lipids and coronary heart disease. Ann Clin Biochem 2005; 42: 254-63. http://dx.doi.org/10.1258/0004563054255605
Hedman M, Miettinen TA, Gylling H, Ketomäki A, Antikainen M. Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy. J Pediat 2006; 148: 241-46. http://dx.doi.org/10.1016/j.jpeds.2005.08.068
Santosa S, Varady KA, AbuMweis S, Jones P. Physilogical and therapeutic factors affecting cholesterol metabolism; Does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci 2007; 80: 505-14. http://dx.doi.org/10.1016/j.lfs.2006.10.006
Nissien MJ, Miettinen TE, Gylling H, Miettinen TA. Applicability of noncholesterol sterols in predicting response in cholesterol metabolism to simvastatin and fluvastatin treatment among hypercholesterolemic men. Nutr Metab Cardiovasc Dis 2010; 20: 308-16. http://dx.doi.org/10.1016/j.numecd.2009.04.014
Assman GK, Kannenberg DR, Ramey TA, et al. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008; 24: 249-59. http://dx.doi.org/10.1185/030079908X253663
Noto D, Cefalu ABC, Barraco G, et al. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. Pediatr Res 2010; 67: 200-204. http://dx.doi.org/10.1203/PDR.0b013e3181c8f035
NCEP Expert panel of blood cholesterol levels in children and Adolescents. National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 1992, 89, 495-501. American Academy of Pediatrics. Statement on Cholesterol. Committee on Nutrition. Pediatrics, 1992, 90, 469-473. The population approach: nutrition recommendations for healthy children and adolescents. Pediatrics 1992; 89: 537-44.
Hyánek J, Martiníková V, Maťoška V, et al. 10 years experience with medical treatment of familial hypercholesterolemia in children and adolescents. Česko-slov. Pediatrie 2006; 61: 404-412. (in Czech with English summary).
Rifkind BM, Segal P. Lipid research clinic program reference values for hyperlipidemia and hypolipidemia. JAMA 1983; 250: 1869-72. http://dx.doi.org/10.1001/jama.1983.03340140039025
Tanner JM. Growth and Adolescence, 2nd ed. Oxford, Blackwell UK 1962.
Francova H, Trbusek M, Zapletalova P, et al. New promoter mutations in the low-density lipoprotein receptor gene which induce familial hypercholesterolemia phenotype. Molecular and functional analysis. J Inher Metab Dis 2004; 27: 523-28. http://dx.doi.org/10.1023/B:BOLI.0000037337.93335.c4
Phillips KM, Ruggio DM, Bailey JA. Precise quantitative determination of phytosterols, stenols, and cholesterol metabolites in human serum, by capillary gas-liquid chromatography. J Chromatog 1999; B732: 17-29. http://dx.doi.org/10.1016/S0378-4347(99)00257-1
Theunissen CE, Regente J, Bergman K, et al. Serum cholesterol precursors and metabolites and cognitive performace in an aging population. Neurobiol Aging 2003; 24: 147-55. http://dx.doi.org/10.1016/S0197-4580(02)00061-1
Descamps OS, DeSutter J, Guillaume M, Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis 2011; 217: 308-21. http://dx.doi.org/10.1016/j.atherosclerosis.2011.06.010
Sudhop T, Reber M, Tribble D, et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009; 50: 2117-23. http://dx.doi.org/10.1194/jlr.P900004-JLR200
Katan MB, Beynen AC. Characteristics of human hypo- and hyperresponders to dietary cholesterol. Am J Epidemiol 1987; 126: 387-99.
Sudhop T, Gottwald BM, Bergman K. Serum plant sterols as a potential risk factor for cardiovascular disease. Metabolism 2002; 51: 1514-21. http://dx.doi.org/10.1053/meta.2002.36298
Sutherlanbd WHF, Williamns MJA, Nye NJ, Restieaux NJ, deJong SA, Walker HL. Associations of plasma noncholesterol sterol levels with severity of coronary artery disease. Nutr Metab Cardiovasc Dis 1998; 8: 389-91.
Weingartner O, Lutjohann D, Vanmierlo T, et al. Markers of enhanced cholesterol absorption are a strong predictor for cardiovascular diseases in patiens without diabetes mellitus. Chem Phys Lipids 2011; 164: 451-56. http://dx.doi.org/10.1016/j.chemphyslip.2011.03.008
MacKay DS, Johes PJH. Plasma noncholesterol sterols: current uses potential and need for standardization. Curr Opin Lipidol 2012; 23: 241-47. http://dx.doi.org/10.1097/MOL.0b013e328353292e
Sudhop T, Gottwald BM, Begmann K. Serum plant sterol as a potential risk factor for cardiovascular disease. Metabolism 2002; 51: 1514-21. http://dx.doi.org/10.1053/meta.2002.36298
Assmann G, Cullen P, Ertey J, et al. Elevation in plasma sitosterol concentration is associated with an increased risk for coronary events in the Procam Study. Circulation 2003; 108(Suppl.): 3300.
MacKay D, Jones PJH. Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. Atherosclerosis 2011; 218: 253-62. http://dx.doi.org/10.1016/j.atherosclerosis.2010.04.022
Thompson GR, O Neil FO, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002; 23: 200-206. http://dx.doi.org/10.1053/euhj.2001.3071
Folch J, Lees M, Sloane Stanley GHS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509.
Thompson RH, Merola GV. A simplified alternative to the AOAC official method for cholesterol in multi-component food. AOAC Int 1993; 76: 1057-68.
Hušek P. Chlormravenčnany v analytické chemii jako činidla rychlé esterifikace. [Chloroformates in analytical chemistry as reagent of rapid esterification; available only in Czech]. Unpublished PhD thesis 1996.
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
